Skip to main content
. Author manuscript; available in PMC: 2021 May 14.
Published in final edited form as: J Med Chem. 2020 Apr 29;63(9):4790–4810. doi: 10.1021/acs.jmedchem.0c00015

Table 6.

Antiviral activity in early-, late-stages of representative compounds using HIV-1 Env-pseudotyped virus.

Compound IC50a (μM) Ratiob
Early Stage Late Stage
6k 8.22 ± 0.99 4.20 ± 2.51 0.51
8a 1.94 ± 0.48 2.44 ± 1.52 1.26
11l 8.96 ± 0.43nM 0.24 ± 0.11 26.79
PF-74 56 ± 17 nM 0.23 ± 0.17 4.11
a

the concentration of the compound required to achieve 50% infection of HIV-1 Env-pseudotyped virus in U87.CD4.CCR5 target cells. SD of 3 parallel tests is indicated.

b

IC50Late/IC50Early ratio.